使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to Align Technologies' Third Quarter 2021 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
各位好,歡迎參加 Align Technologies 2021 年第三季財報電話會議。(接線員指示)提醒各位,本次會議將被錄音。
I would now like to turn the conference over to your host, Shirley Stacy, Vice President of Corporate Communications. Thank you. You may begin.
現在我想將會議交給本次會議主持人——企業傳播副總裁 Shirley Stacy。謝謝。您可以開始了。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Good afternoon, and thank you for joining us. Joining me today for our conference call is Joe Hogan, President and CEO; and John Morici, CFO. We issued third quarter 2021 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com.
各位午安,感謝各位加入我們。今天與我一同參加電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。我們已於今日透過 GlobeNewswire 發布 2021 年第三季財務結果,您可在我們網站 investor.aligntech.com 查閱。
Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on November 10. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13723267, followed by #. International callers should dial (201) 612-7415 with the same conference number.
今天的電話會議將以音訊網路直播,並在我們網站上存檔約 1 個月。電話重播將於今日美東時間約下午 5:30 起提供,至 11 月 10 日美東時間下午 5:30 止。欲收聽電話重播,美國境內來電者請撥打 (877) 660-6853,輸入會議號碼 13723267,並按 #。國際來電者請撥打 (201) 612-7415,並輸入相同會議號碼。
As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission, available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statement.
提醒各位,今天提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件與產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近向美國證券交易委員會(SEC)提交的定期報告中有更詳細的說明,可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不負有更新任何前瞻性陳述之義務。
We have posted historical financial statements, including the corresponding reconciliations on our GAAP -- of our GAAP and non-GAAP reconciliation, if applicable, and our third quarter 2021 conference call slides on our website under quarterly results. Please refer to these files for more detailed information.
我們已在網站「季度結果」專區張貼歷史財務報表(包含相對應的調節表)、GAAP 與非 GAAP 的調節(如適用),以及 2021 年第三季電話會議簡報。請參閱這些檔案以取得更詳細資訊。
And with that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我想把電話交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights in the third quarter, then briefly discuss the performance of our 2 operating segments, Systems Services and Clear Aligners. John will provide more detail on our financial results and discuss our outlook. Following that, I'll come back and summarize a few key points and open the call to questions.
謝謝你,Shirley。各位午安,感謝各位加入我們。今天的電話會議中,我將先提供第三季的一些重點,接著簡要說明我們兩個營運部門——系統與服務(Systems and Services)以及透明牙套(Clear Aligners)的表現。John 將更詳細說明我們的財務結果並討論展望。之後我會回來總結幾個重點並開放提問。
I'm pleased to report strong third quarter results with revenue growth of 38.4% year-over-year on top of a record third quarter last year, driven by the strength across all regions, customer channels and products. For Q3, we shipped to a record 85,500 doctors in the quarter and reached 11.6 million Invisalign patients cumulatively.
我很高興報告第三季表現強勁:在去年第三季創紀錄的高基期之上,營收年增 38.4%,成長動能來自所有地區、客戶通路與產品的全面強勢。第三季我們向創紀錄的 85,500 位醫師出貨,Invisalign 累計治療患者達到 1,160 萬人。
On a sequential basis, Q3 results reflect continued adoption of iTero scanners and increased utilization of Invisalign Clear Aligners in the Americas and APAC regions as well as the growth in Teen segment, especially in the North American orthodontics channel. Our third quarter revenues reflect a growing confidence of doctors and patients with Invisalign treatment, iTero scanners and exocad software as more doctors discover the benefits of digital treatment and transform their practices with the Align Digital Platform.
以季比來看,第三季結果反映 iTero 掃描儀持續被採用,以及美洲與亞太(APAC)地區 Invisalign 透明牙套使用率提升,並且青少年(Teen)業務成長,尤其是在北美矯正通路。第三季營收也反映醫師與患者對 Invisalign 治療、iTero 掃描儀與 exocad 軟體的信心提升;隨著更多醫師發現數位化治療的效益,並透過 Align 數位平台(Align Digital Platform)轉型其診所。
For Q3, Systems and Services revenues were up 57.3% year-over-year with strong revenue growth across all regions and up 5% sequentially primarily in North America. Q3 results reflect the continued adoption of iTero Element 5D Plus Series, our next-generation scanners and imaging system, which launched earlier this year and feature innovative technology like near-infrared technology, we call NIRI, which aids and detection and monitoring of interproximal caries lesions or cavities above the gingiva without harmful radiation.
第三季系統與服務營收年增 57.3%,各地區皆呈現強勁成長;季比成長 5%,主要來自北美。第三季結果反映 iTero Element 5D Plus 系列(我們的新一代掃描與影像系統)持續被採用;該產品於今年稍早推出,具備近紅外線技術(near-infrared technology),我們稱之為 NIRI,可在不使用有害輻射的情況下,協助偵測與監測牙齦上方的鄰接面齲齒病灶或蛀牙。
For Q3, Clear Aligner revenues were up 34.9% year-over-year with strong revenue growth across all regions and across the portfolio, including comprehensive and non-comprehensive products as well as Invisalign Moderate and Invisalign Go. On a sequential basis, Q3 Clear Aligner revenues were down very slightly from record Q2, reflecting more pronounced summer seasonality than last year, especially in EMEA where practices and patients appear to have taken extended holidays and where offices were impacted due to resurgence of COVID-19 cases and restrictions, especially in some markets in Asia Pacific.
第三季透明牙套營收年增 34.9%,各地區及全產品組合皆有強勁成長,包含全方位(comprehensive)與非全方位產品,以及 Invisalign Moderate 與 Invisalign Go。以季比來看,第三季透明牙套營收較創紀錄的第二季僅小幅下滑,反映今年夏季季節性較去年更為明顯,尤其在 EMEA;當地診所與患者似乎延長假期,且部分亞太市場因 COVID-19 病例回升與限制措施再起而影響門診。
In the Teen segment, Q3 '21 Invisalign Clear Aligner volumes for teens were strong, up 13.8% sequentially and 26.6% year-over-year to a record 206,000 teens, representing approximately 1/3 of total cases shipped, with strong shipment growth from North American orthodontists and a record quarter for Teen in APAC.
在青少年(Teen)業務方面,2021 年第三季青少年 Invisalign 透明牙套出貨量表現強勁:季增 13.8%、年增 26.6%,達到創紀錄的 206,000 例青少年病例,約占總出貨病例的三分之一;其中北美矯正醫師出貨成長強勁,亞太地區青少年業務亦創下單季新高。
Our third quarter revenues also include non-case revenue for clinical training and education and doctor-prescribed retainer products. Retention is a critical part of creating and maintaining a beautiful new smile. Retainers prevent teeth from gradually shifting back to their initial positions after treatment ends. Studies show that without retention, even perfectly aligned teeth can gradually revert to their pre-treatment state and that dentition continues to change as patients age, often requiring limited treatment, also known as touch-up treatment if not properly retained.
我們第三季營收亦包含非病例(non-case)營收,例如臨床訓練與教育,以及由醫師處方的維持器(retainer)產品。維持是打造並維持美麗新笑容的關鍵環節。維持器可防止治療結束後牙齒逐漸移回初始位置。研究顯示,若未進行維持,即使牙齒已完美排列,也可能逐步回到治療前狀態;且隨著患者年齡增長,齒列仍會持續變化,若未妥善維持,往往需要有限度治療(亦稱為補強/微調治療,touch-up treatment)。
Our retention products are designed to maintain teeth that have been aligned by Invisalign aligners, braces or other aligners. These retainer products can accommodate lingual bars, wires, also known as a permanent retainer, missing teeth that require an artificial tooth and bite ramps, also known as turbos or blocks.
我們的維持器產品旨在維持經由 Invisalign 牙套、傳統矯正器或其他牙套完成排列的牙齒。這些維持器產品可容納舌側弓(lingual bars)、鋼絲(亦稱永久維持器,permanent retainer)、需要人工牙的缺牙情況,以及咬合墊(bite ramps,亦稱 turbos 或 blocks)。
While our retainer business continues to deliver solid revenue growth, our share of retention market is significantly underpenetrated, even more so than in our share of the orthodontic case starts. We have been developing a robust retainer strategy, including a separate marketing team focused solely on driving adoption and increasing market share in the United States.
雖然我們的維持器業務持續帶來穩健的營收成長,但我們在維持市場的市占率仍明顯不足,甚至比我們在矯正病例起始(orthodontic case starts)市占率的滲透程度更低。我們一直在制定更完善的維持器策略,包括成立一個獨立的行銷團隊,專注於推動美國市場的採用並提升市占率。
Our objective is to build brand awareness for Vivera retainers and drive engagement with doctors through clinical education and sales initiatives, while connecting consumers to doctors through demand creation programs and our concierge service. We've also recently implemented social media campaigns featuring the benefits of Vivera from the makers of Invisalign Clear Aligners. We believe that incremental investments will provide increased value for Invisalign practices and drive growth consistent with our long-term financial model target.
我們的目標是提升 Vivera 維持器的品牌知名度,並透過臨床教育與銷售方案推動醫師參與,同時透過需求創造計畫與我們的禮賓服務(concierge service)將消費者與醫師連結起來。我們近期也推出社群媒體活動,強調由 Invisalign 透明牙套製造商所推出的 Vivera 之優勢。我們相信,這些增量投資將為 Invisalign 診所帶來更高價值,並推動符合我們長期財務模型目標的成長。
In addition, we successfully rolled out a limited pilot program to participating Invisalign providers in the United States and Canada that offers a monthly targeted subscription program to address the unmet patient demand for retention or touch-up cases. Our goal is to encourage experienced high volume in Invisalign practices who regularly treat patients with our comprehensive products to offer premium retention or entry-level products for the long-term health of their patients and to grow their businesses.
此外,我們已在美國與加拿大成功推出一項有限的試點計畫,提供給參與的 Invisalign 供應醫師;該計畫提供每月定向訂閱方案,以滿足患者對維持或補強(touch-up)病例的未被滿足需求。我們的目標是鼓勵具經驗且 Invisalign 病例量高、並經常使用我們全方位產品治療患者的診所,提供高階維持或入門級產品,以促進患者長期口腔健康並擴大其業務。
Practices in this pilot program can purchase a monthly subscription at a fixed price based on their monthly needs for retention or limited treatment. The program allows doctors the flexibility to order both touch-up or retention aligners with their tiered subscription. The program is designed for a segment of experienced Invisalign doctors who are not regularly using our retainers or low-stage aligners.
參與此試點計畫的診所可依其每月對維持或有限度治療的需求,以固定價格購買月訂閱。該方案讓醫師可在分級訂閱下,彈性同時訂購補強或維持用牙套。此計畫鎖定一群具經驗的 Invisalign 醫師,他們並未經常使用我們的維持器或低階段(low-stage)牙套。
The positive feedback from our doctors have been encouraging. For instance, the doctors at Bray and Tarby told us the program is very straightforward and easy to understand, and they've been hoping Align will do something like this. Dr. Jonathan Nicozisis at Princeton Orthodontics called the program a home run. We went -- he went on to predict it should replace the idea that doctors invest in 3D printing and the additional complications and expenses it requires, including the need for a full-time employee and additional overhead costs, particularly because he believes his treatment outcomes are always better with Align.
醫師的正面回饋令人鼓舞。例如,Bray and Tarby 的醫師告訴我們,該方案非常直接、易於理解,他們一直希望 Align 能推出類似方案。Princeton Orthodontics 的 Jonathan Nicozisis 醫師稱該方案是「全壘打」。他接著預測,這應該能取代醫師投資 3D 列印的想法,以及其所需的額外複雜度與費用,包括需要全職員工與額外的管理費用(overhead costs);特別是因為他認為使用 Align 的治療結果總是更好。
Q3 non-case revenues also included accessories and consumables such as aligner cases called clam shells, cleaning crystals and other oral health products that are available on our e-commerce channels in the U.S. only, including the Invisalign accessory store, Walmart and Amazon. In Q3, we announced an exclusive supply distribution agreement with Ultradent Products Inc., a leading developer and manufacturer of high-tech dental materials, devices and instruments worldwide.
第三季非病例營收亦包含配件與耗材,例如稱為 clam shells 的牙套收納盒、清潔結晶(cleaning crystals)及其他口腔健康產品;這些產品僅在美國透過我們的電商通路販售,包括 Invisalign 配件商店、Walmart 與 Amazon。第三季我們宣布與 Ultradent Products Inc. 簽訂獨家供應與經銷協議;Ultradent 為全球領先的高科技牙科材料、設備與器械之開發與製造商。
The Invisalign Professional Whitening program powered by Opalescence is optimized for Invisalign aligners and Vivera retainers and is available only through Invisalign-trained doctors. Also in Q3, we launched the Invisalign Whitening Pen through an e-commerce channels in the U.S. only.
由 Opalescence 技術支援的 Invisalign 專業美白(Invisalign Professional Whitening)計畫,已針對 Invisalign 牙套與 Vivera 維持器進行最佳化,且僅透過受過 Invisalign 訓練的醫師提供。此外在第三季,我們也僅在美國透過電商通路推出 Invisalign 美白筆(Invisalign Whitening Pen)。
The Whitening Pen is an over-the-counter retail product for consumers seeking quick tooth whitening at a lower price and is not intended to be used with aligners. The Whitening Pen complements the other accessory products that Align already markets to consumers through its existing e-commerce channels and is a key addition to our consumable product portfolio.
美白筆是一款供消費者在零售通路購買的非處方產品,適用於希望以較低價格快速進行牙齒美白的消費者,且不打算與隱形牙套搭配使用。美白筆可補強 Align 目前已透過既有電商通路向消費者銷售的其他配件產品,並且是我們消耗性產品組合中的一項關鍵新增品。
Now let's turn to the specifics around our third quarter results, starting with the Americas. For the Americas, Q3 results reflected strong performance, including record revenues for Latin America as well as summer seasonality for adult case starts in North America that primarily impacted GP practices, strong ortho performance, especially in the teen market that included increased utilization from the orthodontic channel.
接下來我們來看第三季業績的細節,先從美洲地區開始。就美洲而言,第三季結果反映出強勁表現,包括拉丁美洲創紀錄的營收,以及北美成人病例啟動的夏季季節性因素(主要影響一般牙科(GP)診所);同時,正畸(ortho)表現強勁,尤其在青少年市場,且來自正畸通路的使用率提升。
Invisalign case volume was up 0.7% sequentially and up 36.4% year-over-year, reflecting growth across the region, especially in LatAm. DSO utilization continued to be a strong growth driver as well, led by Heartland and Smile Docs.
Invisalign 病例量較前一季增加 0.7%,年增 36.4%,反映出整個區域的成長,尤其是拉丁美洲。DSO 的使用率也持續成為強勁的成長動能,主要由 Heartland 與 Smile Docs 帶動。
For our international business, Q3 Invisalign case volume was up 27% year-over-year on top of record growth in the same quarter last year. On a sequential basis, international shipments were down sequentially 4.3%, primarily as a result of greater seasonality and COVID-related shutdowns in APAC markets. For EMEA, Q3 Invisalign case volumes were up 49.6% year-over-year, with broad-based growth across all markets led by the U.K. and Iberia, along with continued growth in our expansion markets in Central and Eastern Europe and the Benelux.
在國際業務方面,第三季 Invisalign 病例量在去年同期創紀錄成長的高基期之上,仍年增 27%。以季比來看,國際出貨量較前一季下降 4.3%,主要因季節性更為明顯,以及亞太(APAC)市場與 COVID 相關的停工停業影響。就 EMEA 而言,第三季 Invisalign 病例量年增 49.6%,各市場普遍成長,由英國與伊比利亞半島領軍,同時我們在中東歐與比荷盧等擴張市場也持續成長。
For Q3, year-over-year Invisalign volume in EMEA was driven by increased submitters from both orthodontists and GPs and increased utilization primarily from orthos. On a sequential basis, EMEA was down sequentially 16.5% following a record Q2, primarily as a result of the extended seasonality we had anticipated primarily from summer holidays and vacations across the region.
第三季 EMEA 的 Invisalign 病例量年增,主要來自正畸醫師與一般牙科(GP)兩個族群的提交者(submitters)增加,以及主要由正畸端帶動的使用率提升。以季比來看,EMEA 在第二季創紀錄後,第三季較前一季下降 16.5%,主要因我們先前預期的延長季節性影響,主要來自區域內的暑假與休假。
For APAC, Q3 volumes were up 4.2% compared to a record Q3 last year in APAC. On a year-over-year basis, growth was uneven. The market as APAC, the first region to emerge from the depths of the COVID lockdown in 2020. Additionally, we saw COVID resurgences and lockdowns sporadically impact various APAC countries in Q3.
在亞太(APAC)方面,第三季量較去年亞太創紀錄的第三季增加 4.2%。以年比來看,成長並不均衡。亞太是 2020 年最早走出 COVID 封鎖低谷的第一個區域。此外,我們也看到第三季期間,COVID 再度升溫與封鎖措施零星影響多個亞太國家。
On a sequential basis, Q3 Invisalign volumes were up 21.2% reflecting growth across the region, led by a record quarter in China, especially from teen cases as well as strong growth in Japan and ANZ. And Q3, growth from both channels was strong, with ortho growth driven by increased Invisalign utilization and GP growth -- channel growth driven by increased Invisalign submitters.
以季比來看,第三季 Invisalign 量增加 21.2%,反映出整個區域的成長,由中國創紀錄的一季領軍,尤其是青少年病例,同時日本與澳洲及紐西蘭(ANZ)也有強勁成長。而在第三季,兩個通路的成長都很強勁:正畸通路的成長由 Invisalign 使用率提升帶動;一般牙科(GP)通路的成長則由 Invisalign 提交者增加所驅動。
APAC teen shipments reached an all-time high in Q3. At the recent 10th China Finance Summit Awards, Align was recognized as the 2021 most innovative enterprise for its advancements and outstanding contributions in the field of digital orthodontics. This award builds on our prior recognition of Align's leadership in the digital orthodontics industry and its efforts to promote the modernization of orthodontics.
亞太青少年出貨量在第三季創下歷史新高。在近期第十屆中國財經峰會頒獎典禮上,Align 因其在數位正畸領域的進展與卓越貢獻,獲評為 2021 年最具創新力企業。此獎項延續了我們先前對 Align 在數位正畸產業領導地位的肯定,以及其推動正畸現代化的努力。
Our consumer marketing focuses on educating consumers about the Invisalign system to drive demand to Invisalign doctor's offices, ultimately capitalizing on the massive market opportunity to transform 500 million smiles.
我們的消費者行銷聚焦於教育消費者了解 Invisalign 系統,以帶動需求導流至 Invisalign 醫師診所,最終把握龐大的市場機會,改變 5 億個笑容。
In Q3, we expanded the next generation of the "Invis is" media campaign across EMEA, APAC and Brazil to increase awareness with adult, mom and teen consumers. Globally, we delivered 6.45 billion impressions, growing 42% year-over-year, resulting in a 70% year-over-year increase in unique visitors to our websites.
第三季,我們在 EMEA、APAC 與巴西擴大推出新一代「Invis is」媒體行銷活動,以提升成人、媽媽與青少年消費者的認知度。在全球範圍內,我們累計觸及 64.5 億次曝光(impressions),年增 42%,並帶動我們網站的獨立訪客數年增 70%。
In the U.S., we connected with teens on Snapchat, YouTube and Twitch with our "Invis is Not Your Parents Braces" campaign. These campaigns continue to feature some of the largest teen influencers from our Invisalign Smile Squad, like Charli D'Amelio, Marsai Martin, [Michael Lynn Collins] and Devon Key. These influencers share their personal experience with Invisalign treatment, including why they chose Invisalign treatment to shape their smiles.
在美國,我們透過「Invis is Not Your Parents Braces」活動在 Snapchat、YouTube 與 Twitch 與青少年建立連結。這些活動持續邀請 Invisalign Smile Squad 中一些最具影響力的青少年網紅,例如 Charli D'Amelio、Marsai Martin、[Michael Lynn Collins] 與 Devon Key。這些網紅分享他們使用 Invisalign 治療的個人經驗,包括他們為何選擇 Invisalign 來塑造自己的笑容。
As part of our focus on teens, with our Invisalign ChangeMakers program, we held a recognition event hosted by Marsai Martin, with teens across the country to celebrate and recognize 100 teens across the country who drove positive change within their communities.
作為我們聚焦青少年的一部分,透過 Invisalign ChangeMakers 計畫,我們舉辦了一場由 Marsai Martin 主持的表揚活動,與全國各地的青少年一同慶祝並表揚 100 位在其社區推動正向改變的青少年。
To continue growing for our young adult businesses, we expanded the "Invis is a Powerful Thing" campaign, which highlights how powerful the smile transformation with Invisalign treatment can be for their self-confidence. In the U.S., we expanded our Invisalign Smile Squad to include young adult influencers such as Cody Rigsby, Lana Condor and Emily Hampshire, will help to deliver over 405 million impressions. Additionally, our influencer partnerships with TikTok creators helped increase traffic to our sites with a 127% increase in click-through rates.
為了持續推動年輕成人業務成長,我們擴大「Invis is a Powerful Thing」活動,強調 Invisalign 治療帶來的笑容改變,對自信心能有多大的力量。在美國,我們擴編 Invisalign Smile Squad,納入 Cody Rigsby、Lana Condor 與 Emily Hampshire 等年輕成人網紅,將有助於帶來超過 4.05 億次曝光。此外,我們與 TikTok 創作者的網紅合作也協助提升網站流量,點擊率(click-through rates)提高 127%。
In Brazil, we launched the "Invis is a Powerful Thing" campaign and teamed up with mega-influencer, (inaudible) to increase website traffic by 30%. In the EMEA region, we expanded into new media channels such as TikTok and Snapchat across the U.K., Germany and France to drive engagement. These efforts led to more than 153% increase in unique visitors. We also started consumer advertising in Russia, which resulted in more of a 1,000 increase in unique visitors to our website.
在巴西,我們推出「Invis is a Powerful Thing」活動,並與超級網紅(聽不清)合作,使網站流量提升 30%。在 EMEA 地區,我們在英國、德國與法國擴展至 TikTok 與 Snapchat 等新媒體通路以提升互動,帶動獨立訪客數增加超過 153%。我們也在俄羅斯開始投放消費者廣告,使我們網站的獨立訪客數增加超過 1,000。
In Q3, we continue to expand our consumer advertising across the APAC region, experienced a 132% increase in unique visitors to our websites. In Australia, we expanded our media mix to include partners such as TikTok and Snapchat, which resulted in a 250% growth year-over-year in unique visitors to our website.
第三季,我們持續在亞太地區擴大消費者廣告投放,使我們網站的獨立訪客數增加 132%。在澳洲,我們擴大媒體組合,納入 TikTok 與 Snapchat 等合作夥伴,使網站獨立訪客數年增 250%。
In Japan, we continue to see a strong response from consumers to our "Invis is" campaign, resulting to more than an 800% increase year-over-year in unique visitors to our website. Adoption of our consumer and patient app, My Invisalign, continued to increase in Q3 with 1.2 million downloads to date. Usage of our 4 digital tools also continue to increase.
在日本,消費者對我們「Invis is」活動的反應持續強勁,使我們網站的獨立訪客數年增超過 800%。我們的消費者與患者 App「My Invisalign」的採用在第三季也持續提升,累計下載量達 120 萬次。我們的 4 項數位工具使用量也持續增加。
For example, our Invisalign Virtual Appointment tool was used over 15,000 times and our insurance verification feature was used 14,000 times in Q3. Furthermore, we received more than 1.5 million patient photos in our Virtual Care feature to date globally, which continues to provide us with rich data to leverage our AI capabilities and improve our services for doctors that is used to enhance their patient's care.
例如,我們的 Invisalign Virtual Appointment(虛擬約診)工具在第三季使用超過 15,000 次,而保險驗證功能使用 14,000 次。此外,截至目前我們在全球的 Virtual Care 功能已收到超過 150 萬張患者照片,持續為我們提供豐富資料,以運用 AI 能力並改善提供給醫師的服務,進而提升其對患者的照護。
For our Systems and Services business, Q3 revenues grew 57.3% year-over-year reflecting strong scanner shipments and services and was up 5% sequentially. This is the fifth consecutive quarter of sequential revenue growth for our Systems and Services business. The iTero Element 5D Plus imaging system continued gaining traction across all regions, with the most recent launch in Japan in Q3. The iTero Element 5D Plus imaging system will be available in China in Q4 of this year. Additionally, the iTero Element Plus Series was launched in Korea in Q3.
在系統與服務(Systems and Services)業務方面,第三季營收年增 57.3%,反映出掃描儀出貨與服務表現強勁,且季增 5%。這是我們系統與服務業務連續第五季營收季增。iTero Element 5D Plus 影像系統持續在各區域獲得採用,並於第三季在日本完成最新上市。iTero Element 5D Plus 影像系統將於今年第四季在中國上市。此外,iTero Element Plus 系列也於第三季在韓國上市。
The series expands the portfolio of iTero Element scanners and imaging systems to include new solutions that serve the needs of a broader range of doctors and patients in the dental market. Moreover, I'm proud to say that in a recent clinical study, the iTero Element 5D intraoral scanner was found to be more sensitive than bitewing radiology in detecting early enamel lesions, providing further evidence of the benefits of iTero 5D scanner in detection and monitoring of interproximal caries lesions or cavities above the gingiva without exposing patients to harmful ionizing radiation.
該系列擴充 iTero Element 掃描儀與影像系統的產品組合,新增可滿足牙科市場中更廣泛醫師與患者需求的解決方案。此外,我也很自豪地表示,在近期一項臨床研究中,iTero Element 5D 口內掃描儀在偵測早期琺瑯質病灶方面,被發現比咬翼片 X 光(bitewing radiology)更敏感,進一步證明 iTero 5D 掃描儀在偵測與監測牙齦以上、鄰接面齲齒病灶或蛀牙方面的效益,且無需讓患者暴露於有害的游離輻射。
This is great news for our iTero business as the study further supports the diagnostic validity of near-infrared imaging technology offered by the iTero 5D scanner for early proximal caries detection.
這對我們的 iTero 業務而言是非常好的消息,因為該研究進一步支持 iTero 5D 掃描儀所提供的近紅外線影像(near-infrared imaging)技術在早期鄰接面齲齒偵測上的診斷有效性。
The findings also underscore the valuable role that NIRI technology can have in dental health assessment and early detection of cavities, which is important to the overall oral health care treatment options and a comfortable safe experience for a broad population of patients. A strong indicator of the digital acceleration with dental offices is a number of intraoral digital scans used for Invisalign case submissions.
研究結果也凸顯 NIRI 技術在牙科健康評估與早期蛀牙偵測方面可扮演的重要角色,這對整體口腔健康照護的治療選項,以及讓廣大患者族群獲得舒適且安全的體驗都很重要。衡量牙科診所數位加速的一項強力指標,是用於 Invisalign 病例提交的口內數位掃描數量。
Total worldwide intraoral digital scans used to start in Invisalign case in Q3 increased 84.2% from 78.3% in Q3 last year. International intraoral digital scans for Invisalign case submissions increased 79.3%, up from 72.1% in the same last year.
第三季用於啟動 Invisalign 病例的全球口內數位掃描占比提升至 84.2%,高於去年第三季的 78.3%。國際市場用於提交 Invisalign 病例的口內數位掃描占比提升至 79.3%,高於去年同期的 72.1%。
For the Americas, 88% of cases were submitted using an intraoral digital scan compared to 83.2% a year ago. Cumulatively, over 44.9 million orthodontic scans and 9.3 million restorative scans have been performed with iTero scanners.
在美洲地區,88% 的病例以口內數位掃描提交,較一年前的 83.2% 提升。累計而言,使用 iTero 掃描儀已完成超過 4,490 萬次矯正掃描與 930 萬次修復掃描。
Our Q3 Systems and Services revenues also includes exocad, CAD/CAM products and services. exocad's expertise in restorative dentistry, implantology, guided surgery and smile design, extends our digital dental solutions and broadens Align's digital platform towards fully integrated interdisciplinary and workflows. We remain excited about our continued integration progress and product plans with exocad.
我們第三季的系統與服務營收亦包含 exocad、CAD/CAM 產品與服務。exocad 在修復牙科、植牙學、導引手術與微笑設計方面的專業,擴展了我們的數位牙科解決方案,並使 Align 的數位平台朝向完全整合的跨專科與工作流程發展。我們對與 exocad 持續整合的進展與產品規劃仍感到振奮。
During the quarter, exocad launched ChairsideCAD 3.0 Galway, the next generation of exocad's easy-to-use CAD software for single-visit dentistry. The software has improved automation for fast crown design and enables users to integrate open hardware and materials of choice. exocad's ChairsideCAD received 2021 Cellerant's Best of Class Technology Award for the third consecutive year.
本季期間,exocad 推出 ChairsideCAD 3.0 Galway,這是 exocad 易用 CAD 軟體的下一代版本,適用於單次就診牙科。該軟體提升自動化程度以加速牙冠設計,並讓使用者可整合開放式硬體與自選材料。exocad 的 ChairsideCAD 連續第三年獲得 2021 年 Cellerant「同級最佳」科技獎。
Also during the quarter, exocad had its largest ever presence at IDS, the International Dental Show, where they showcased their seamless digital workflows and the simplicity of the use of exocad's Galway software release. exocad was the only company at IDS to showcase live patient treatment with a smile creator experience station, featuring iTero's scans, instant smile makeovers and production of clip-on smiles.
同樣在本季,exocad 於國際牙科展(IDS)創下歷來最大規模的參展陣容,展示其無縫的數位工作流程,以及 exocad Galway 軟體版本的易用性。exocad 是 IDS 唯一展示真人患者即時治療的公司,並設置微笑創作體驗站,結合 iTero 掃描、即時微笑改造,以及製作可夾式微笑裝置。
With that, I'll now turn it over to John.
接下來,我把時間交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q3 financial results. Total revenues for the third quarter were $1.016 billion, up 0.5% from the prior quarter and up 38.4% from the corresponding quarter a year ago. For Clear Aligners, Q3 revenues of $837.6 million were down 0.4% sequentially and up 34.9% year-over-year, reflecting Invisalign volume growth across all geographies.
謝謝,Joe。接著說明我們第三季的財務結果。第三季總營收為 10.16 億美元,較前一季成長 0.5%,較去年同期成長 38.4%。在透明牙套(Clear Aligners)方面,第三季營收為 8.376 億美元,較前一季下降 0.4%,較去年同期成長 34.9%,反映 Invisalign 在各地區的出貨量成長。
In Q3, we shipped 655,100 Invisalign cases, a decrease of 1.6% sequentially with an increase of 32.1% year-over-year. In addition, we shipped to a record 85,500 Invisalign doctors worldwide, of which approximately 7,200 were first-time customers.
第三季我們出貨 655,100 件 Invisalign 病例,較前一季減少 1.6%,較去年同期增加 32.1%。此外,我們向全球創紀錄的 85,500 位 Invisalign 醫師出貨,其中約 7,200 位為首次購買客戶。
Q3 Clear Aligner revenues reflect strong growth across the Invisalign portfolio, led by comprehensive products. Q3 comprehensive volume increased 1.3% sequentially and 30.3% year-over-year. And Q3 non-comprehensive volume decreased 8.1% sequentially and increased 36.8% year-over-year. Q3 adult patients decreased 7.3% sequentially and increased 34.7% year-over-year. In Q3, teens or younger patients increased 13.8% sequentially and 26.6% year-over-year.
第三季透明牙套營收反映 Invisalign 產品組合的強勁成長,其中以全方案產品帶動為主。第三季全方案出貨量較前一季增加 1.3%,較去年同期增加 30.3%。第三季非全方案出貨量較前一季下降 8.1%,較去年同期增加 36.8%。第三季成人患者較前一季下降 7.3%,較去年同期增加 34.7%。第三季青少年或更年輕患者較前一季增加 13.8%,較去年同期增加 26.6%。
Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $1.5 million or approximately 0.2 points sequentially. On a year-over-year basis, Clear Aligner revenues were favorably impacted by foreign exchange of approximately $16.1 million or approximately 2.6 points.
透明牙套營收受到外匯不利影響約 150 萬美元,或約 0.2 個百分點(相較前一季)。以年對年而言,透明牙套營收受到外匯有利影響約 1,610 萬美元,或約 2.6 個百分點。
For Q3, Invisalign comprehensive ASPs increased sequentially and year-over-year. On a sequential basis, Invisalign comprehensive ASPs reflect higher additional aligners. On a year-over-year basis, comprehensive ASPs reflect favorable foreign exchange, partially offset by the increase in net revenue deferrals for new Invisalign cases versus additional aligner shipments.
第三季 Invisalign 全方案 ASP(平均銷售單價)較前一季與去年同期皆上升。就季對季而言,Invisalign 全方案 ASP 反映額外牙套(additional aligners)增加。就年對年而言,全方案 ASP 反映外匯有利影響,但部分被新 Invisalign 病例相較於額外牙套出貨所帶來的淨營收遞延增加所抵銷。
Q3 Invisalign non-comprehensive ASPs increased sequentially and year-over-year. On a sequential basis, Invisalign non-comprehensive ASPs reflect higher additional aligners, partially offset by higher discounts. On a year-over-year basis, Invisalign non-comprehensive ASPs were favorably impacted by foreign exchange, higher additional aligners and lower discounts.
第三季 Invisalign 非全方案 ASP 較前一季與去年同期皆上升。就季對季而言,Invisalign 非全方案 ASP 反映額外牙套增加,但部分被折扣提高所抵銷。就年對年而言,Invisalign 非全方案 ASP 受到外匯有利影響、額外牙套增加以及折扣降低的帶動。
Clear Aligner deferred revenues on the balance sheet increased $84 million or 9.3% sequentially and $347.3 million or 53.9% year-over-year and will be recognized as the additional aligners are shipped. Our Systems and Services revenues for the third quarter were a record $178.3 million, up 5% sequentially and up 57.3% year-over-year. This marks the fifth quarter in a row of sequential revenue increase.
資產負債表上的透明牙套遞延營收較前一季增加 8,400 萬美元(9.3%),較去年同期增加 3.473 億美元(53.9%),並將在額外牙套出貨時認列。第三季系統與服務營收創下 1.783 億美元新高,較前一季成長 5%,較去年同期成長 57.3%。這是連續第五季營收季增。
The increase sequentially can be attributed to increased scanner shipments and increased services revenues from our larger installed base. The increase year-over-year can be attributed to increased scanner shipments, increased service revenues from our larger installed base as well as higher ASPs from a favorable mix shift towards higher-priced iTero 5D scanners and imaging systems.
季對季的增加可歸因於掃描儀出貨增加,以及因裝機基數擴大而帶來的服務營收增加。年對年的增加可歸因於掃描儀出貨增加、因裝機基數擴大而帶來的服務營收增加,以及因產品組合有利轉向較高單價的 iTero 5D 掃描儀與影像系統而帶動 ASP 提升。
Our Systems and Services deferred revenue on the balance sheet was up $27.2 million or 17% sequentially and up $100.1 million or 115.2% year-over-year, primarily due to the increase in scanner sales and deferral of services revenue, which we recognize ratably over the service period.
資產負債表上的系統與服務遞延營收較前一季增加 2,720 萬美元(17%),較去年同期增加 1.001 億美元(115.2%),主要由於掃描儀銷售增加與服務營收遞延增加;我們會在服務期間按比例認列該等服務營收。
Moving on to gross margin. Third quarter overall gross margin was 74.3%, down 0.7 points sequentially and up 1.6 points year-over-year. On a non-GAAP basis, excluding stock-based compensation and amortization of intangibles related to our 2020 exocad acquisition, overall gross margin was 74.7% for the third quarter, down 0.7 points sequentially and up 1.4 points year-over-year.
接著談毛利率。第三季整體毛利率為 74.3%,較前一季下降 0.7 個百分點,較去年同期上升 1.6 個百分點。以非 GAAP 基礎(排除以股份為基礎的薪酬,以及與 2020 年收購 exocad 相關的無形資產攤銷)計算,第三季整體毛利率為 74.7%,較前一季下降 0.7 個百分點,較去年同期上升 1.4 個百分點。
Overall gross margin was favorably impacted by approximately 0.5 points on a year-over-year basis due to foreign exchange and relatively unchanged sequentially. Clear Aligner gross margin for the third quarter was 76.2%, down 0.7 points sequentially due to higher manufacturing costs and higher additional aligners, partially offset by higher ASPs and lower freight. Clear Aligner gross margin was up 1.5 points year-over-year due to improved manufacturing efficiencies from higher production volume, partially offset by higher ASPs.
整體毛利率在年對年基礎上因外匯而約有 0.5 個百分點的有利影響,季對季則大致持平。第三季透明牙套毛利率為 76.2%,較前一季下降 0.7 個百分點,主要因製造成本較高及額外牙套增加,部分被 ASP 提升與運費降低所抵銷。透明牙套毛利率較去年同期上升 1.5 個百分點,主要因產量提高帶來製造效率改善,部分被 ASP 較高所抵銷。
Systems and Services gross margin for the third quarter was 65.6%, down 0.3 points sequentially primarily due to lower ASPs and higher manufacturing variances, partially offset by higher service revenue. Systems and Services gross margin was up 3.6 points year-over-year due to higher ASPs from product mix shift to iTero 5D and 5D Plus Series and service revenues, partially offset by higher freight cost.
第三季系統與服務毛利率為 65.6%,較前一季下降 0.3 個百分點,主要因 ASP 較低與製造差異較高,部分被服務營收較高所抵銷。系統與服務毛利率較去年同期上升 3.6 個百分點,主要因產品組合轉向 iTero 5D 與 5D Plus 系列及服務營收帶動 ASP 提升,部分被運費成本較高所抵銷。
Q3 operating expenses were $494 million, up sequentially 0.9% and up 38.4% year-over-year. On a sequential basis, operating expenses were up slightly by $4.4 million. Year-over-year, operating expenses increased by $137 million, reflecting increased headcount and our continued investment in marketing, sales and R&D activities and investments commensurate with business growth.
第三季營業費用為 4.94 億美元,較前一季增加 0.9%,較去年同期增加 38.4%。就季對季而言,營業費用小幅增加 440 萬美元。就年對年而言,營業費用增加 1.37 億美元,反映人員編制增加,以及我們持續投入行銷、銷售與研發活動,並隨業務成長進行相應投資。
On a non-GAAP basis, excluding stock-based compensation and amortization of intangibles and acquisition costs related to our 2020 exocad acquisition, operating expenses were $466.1 million, up sequentially 1% and up 40.3% year-over-year due to the reasons described earlier.
以非 GAAP 基礎(排除以股份為基礎的薪酬、無形資產攤銷,以及與 2020 年收購 exocad 相關的收購成本)計算,營業費用為 4.661 億美元,較前一季增加 1%,較去年同期增加 40.3%,原因如前所述。
Our third quarter operating income of $261.1 million resulted in an operating margin of 25.7%, down 0.9 points from the prior quarter and up 1.6 points year-over-year. The sequential decrease in operating margin was attributable primarily to lower gross margin. The year-over-year increase in operating margin was primarily attributed to higher gross margin and operating leverage as well as the favorable impact from foreign exchange by approximately 0.7 points, partially offset by continued investments as mentioned earlier.
第三季營業利益為 2.611 億美元,營業利益率為 25.7%,較前一季下降 0.9 個百分點,較去年同期上升 1.6 個百分點。營業利益率季對季下降主要歸因於毛利率較低。營業利益率年對年上升主要歸因於毛利率較高與營運槓桿,以及外匯約 0.7 個百分點的有利影響;部分被前述持續投資所抵銷。
On a non-GAAP basis, which excludes stock-based compensation and amortization of intangibles and acquisition-related costs, the operating margin for the third quarter was 28.8%, down 0.9 points sequentially and up 0.8 points year-over-year. Interest and other income and expense net for the third quarter was a gain of $0.8 million, up sequentially by $0.9 million and down year-over-year by $6.6 million.
以非 GAAP 基礎(排除以股份為基礎的薪酬、無形資產攤銷及收購相關成本)計算,第三季營業利益率為 28.8%,較前一季下降 0.9 個百分點,較去年同期上升 0.8 個百分點。第三季利息及其他收益與費用淨額為收益 80 萬美元,較前一季增加 90 萬美元,較去年同期減少 660 萬美元。
On a year-over-year basis, interest and other income and expense decreased primarily due to net foreign exchange losses in the 3 months ended September 30, 2021, as compared to net foreign exchange gains in the same period in 2020, which was partially offset by an unrealized gain on an investment held in a private company recognized in the 3 months ended September 30, 2021.
以年對年基礎來看,利息及其他收入與費用的下降,主要係因截至2021年9月30日止三個月錄得淨外匯損失,相較於2020年同期錄得淨外匯收益;此影響部分被截至2021年9月30日止三個月就持有之私人公司投資所認列的未實現收益所抵銷。
The GAAP effective tax rate for the third quarter was 30.9% compared to 25.7% in the second quarter and 24.5% in the third quarter of the prior year. On a non-GAAP -- our non-GAAP effective tax rate was 22.2% in the third quarter compared to 19.5% in the second quarter and 16.6% in the third quarter of the prior year. The third quarter GAAP and non-GAAP effective tax rates were higher than the second quarter primarily due to our foreign income being taxed at different rates and tax true-ups.
第三季GAAP有效稅率為30.9%,相較第二季為25.7%,且相較去年同期第三季為24.5%。以非GAAP口徑—我們的非GAAP有效稅率第三季為22.2%,相較第二季為19.5%,且相較去年同期第三季為16.6%。第三季GAAP與非GAAP有效稅率高於第二季,主要係因我們海外所得適用不同稅率課稅,以及稅務調整(tax true-ups)。
Our GAAP and non-GAAP third quarter effective tax rates were higher than the third quarter of the prior year primarily due to lower tax benefits from foreign income tax at lower rates and a tax benefit recognized last year resulting from an income tax audit settlement. Third quarter net income per diluted share was $2.28, down sequentially $0.23 and up $0.52 compared to the prior year. On a non-GAAP basis, net income per diluted share was $2.87 for the third quarter, down $0.17 sequentially and up $0.62 year-over-year.
我們第三季GAAP與非GAAP有效稅率高於去年同期第三季,主要係因海外所得以較低稅率課稅所帶來的稅務利益減少,以及去年因所得稅稽核和解而認列的一項稅務利益。第三季稀釋後每股淨利為2.28美元,較前一季下降0.23美元,較去年同期增加0.52美元。以非GAAP口徑,第三季稀釋後每股淨利為2.87美元,較前一季下降0.17美元,年對年增加0.62美元。
Moving on to the balance sheet. As of September 30, 2021, cash and cash equivalents were $1.2 billion, up sequentially $151.5 million and up $622.3 million year-over-year. Of our $1.2 billion of cash and cash equivalents, $607.5 million was held in the U.S. and $630.3 million was held by our international entities.
接著看資產負債表。截至2021年9月30日,現金及約當現金為12億美元,較前一季增加1.515億美元,年對年增加6.223億美元。在我們12億美元的現金及約當現金中,6.075億美元持有於美國,6.303億美元由我們的國際實體持有。
Q3 accounts receivable balance was $855 million, up approximately 5.8% sequentially. Our overall days sales outstanding was 75 days, up approximately 3 days sequentially and down approximately 2 days as compared to Q3 last year.
第三季應收帳款餘額為8.55億美元,較前一季約增加5.8%。整體應收帳款週轉天數(DSO)為75天,較前一季約增加3天,較去年第三季約減少2天。
Cash flow from operations for the third quarter was $355 million. Capital expenditures for the third quarter were $124.3 million as we continued to invest in increasing aligner capacity and facilities. Free cash flow, defined as cash flow from operations less capital expenditures, amounted to $230.7 million. We also have $300 million available under our untapped revolving line of credit. Under our $1 billion repurchase program announced in May of 2021, we have $825 million remaining available for repurchase of our common stock.
第三季營運活動現金流量為3.55億美元。第三季資本支出為1.243億美元,因我們持續投資以提升隱形矯正器產能與設施。自由現金流量(定義為營運活動現金流量減資本支出)為2.307億美元。我們亦有3億美元可用額度,來自尚未動用的循環信用額度。在我們於2021年5月宣布的10億美元庫藏股回購計畫下,尚有8.25億美元可用於回購普通股。
Now let me turn to our outlook and the factors that inform our view for the remainder of the year. We are very pleased with our Q3 results and strong year-over-year growth, which reflects continued customer adoption of the iTero scanners and increased Invisalign utilization across customer channels, including teens, adults and young patients.
接下來談談我們的展望,以及支撐我們對今年剩餘期間看法的因素。我們對第三季成果與強勁的年對年成長感到非常滿意,這反映客戶持續採用iTero掃描儀,以及Invisalign在各客戶通路(包括青少年、成人與年幼患者)中的使用率提升。
Over the last 18 months, our investment decisions have helped drive and capture demand across all regions and customer channels. We continued spending in many areas and have seen good return on our investments and strong revenue growth. Consumer interest in improving smiles is high and doctor acceptance in the Align Digital Platform is helping drive growth across all regions and market segments.
過去18個月,我們的投資決策有助於在所有地區與客戶通路推動並掌握需求。我們在多個領域持續投入,並已看到良好的投資報酬與強勁的營收成長。消費者對改善笑容的興趣維持高檔,而醫師對Align數位平台(Align Digital Platform)的接受度正協助推動各地區與各市場區隔的成長。
As anticipated in our Q3 outlook, we experienced more pronounced summer seasonality, more noticeably in September and continued into October as practices took more extended vacations and patient traffic flow was sporadically interrupted by regional COVID resurgence, restrictions and other lockdowns. We anticipate these COVID challenges and the general macroeconomic uncertainties to continue into Q4.
如我們在第三季展望中所預期,我們經歷了更為明顯的夏季季節性,9月尤為顯著並延續至10月,因診所休較長假期,且患者就診流量亦因各地COVID再度升溫、限制措施及其他封鎖而間歇性受干擾。我們預期這些COVID挑戰以及整體宏觀經濟不確定性將延續至第四季。
Taking this all into account, as we look at the remainder of 2021, we expect revenues for the year to be in the range of $3.9 billion to $3.95 billion, at the high end of our original guidance range. We also expect our outlook and revenue growth for the second half of 2021 to be in the high end of our long-term operating model of 20% to 30%. On a GAAP basis, we anticipate our 2021 operating margin to be around 25%. On a non-GAAP basis, we expect 2021 operating margin to be approximately 3 points higher than our GAAP operating margin after excluding stock-based compensation and intangible amortization from our 2020 exocad acquisition.
綜合以上因素,展望2021年剩餘期間,我們預期全年營收將介於39億至39.5億美元,位於我們原先指引區間的高端。我們亦預期2021年下半年展望與營收成長將落在我們長期營運模型20%至30%的高端。以GAAP口徑,我們預期2021年營業利益率約為25%。以非GAAP口徑,在排除股票基礎薪酬以及2020年收購exocad所產生之無形資產攤銷後,我們預期2021年營業利益率將較GAAP營業利益率高約3個百分點。
We remain confident in the huge market opportunities for our business, our industry leadership and our ability to execute. We will continue to invest in sales, marketing, innovation and manufacturing capacity to drive our growth and accelerate adoption in a huge underpenetrated market. In addition, during Q4 2021, we expect to repurchase up to $100 million of our common stock through either a combination of open-market repurchases or an accelerated stock repurchase agreement.
我們仍對本業龐大的市場機會、產業領導地位以及執行能力充滿信心。我們將持續投資於銷售、行銷、創新與製造產能,以推動成長並加速在這個滲透率仍低的龐大市場中的採用。此外,在2021年第四季期間,我們預期將透過公開市場回購或加速股票回購協議(或兩者組合)回購最多1億美元的普通股。
For 2021, we expect our investments in capital expenditures to be above $400 million. Capital expenditures primarily relate to building construction improvements as well as additional manufacturing capacity to support our international expansion. This includes our planned investment in our new facility in Wroclaw, Poland, the first in the EMEA region.
2021年,我們預期資本支出投資將高於4億美元。資本支出主要與建築工程改善以及增加製造產能以支持國際擴張相關。其中包括我們計畫投資於波蘭弗羅茨瓦夫(Wroclaw)新設施,這將是我們在EMEA地區的第一座設施。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來我把時間交回Joe做最後評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John. In summary, Q3 was a strong quarter, and we're pleased with our performance across the business. Align is uniquely positioned. We have the clinical capability and product portfolio supported by doctor and patient workflows, only accessible through the proprietary Align Digital Platform to address the broadest range of orthodontic cases with the Invisalign system through a network of trained Invisalign doctors who have the expertise to reach more than the 500 million potential global patients.
謝謝,John。總結來說,第三季表現強勁,我們對公司各業務的表現感到滿意。Align具備獨特優勢。我們擁有臨床能力與產品組合,並由醫師與患者的工作流程所支援,且僅能透過專有的Align數位平台(Align Digital Platform)取得;我們可透過由受訓的Invisalign醫師所組成的網絡,以Invisalign系統處理最廣泛的齒顎矯正病例,這些醫師具備專業能力,可觸及全球超過5億名潛在患者。
As we develop our annual plan for 2022 over the next few months, it's important that we continue to expand our commercial, manufacturing, R&D, clinical, treatment planning and manufacturing operations. And continue to leverage our global quality and regulatory muscles in existing and emerging markets. Reach millions of consumers who want to transform their smile with the most advanced Clear Aligner systems in the world.
在接下來幾個月制定2022年年度計畫的過程中,重要的是我們要持續擴大商業、製造、研發、臨床、治療規劃與製造營運,並持續運用我們在既有與新興市場的全球品質與法規能力,觸及數以百萬計希望以全球最先進的透明矯正器系統改變笑容的消費者。
Through advertising, PR, digital, social media and influencer marketing to drive demand and conversion through Invisalign-trained doctors. Increased ortho adoption and teen utilization of Invisalign treatment and train and educate GP dentists on how the iTero Element family of intraoral scanners and imaging systems propel today's dental practice into the future by enhancing patient experience and elevating clinical precision, and in the benefits of digital dentistry with the Invisalign system, trusted by more than 11 million people worldwide to improve their smiles.
透過廣告、公關、數位、社群媒體與網紅行銷,推動需求並透過受訓的Invisalign醫師提升轉換。提高齒顎矯正採用率與青少年Invisalign治療使用率,並訓練與教育一般牙科(GP)牙醫,了解iTero Element系列口內掃描儀與影像系統如何透過提升患者體驗與臨床精準度,推動今日牙科診所邁向未來,以及了解以Invisalign系統實現數位牙科的效益;該系統已獲全球超過1,100萬人信賴,用以改善笑容。
We remain focused on strategic execution, accountability, agility, customer service excellence and continuing to make investments to grow our business. This is a multivariable equation that we continue to talk about and that, in combination, we remain uniquely able to offer. As we continue to stay the course with our strategic initiatives, we also continue to navigate the COVID-19 environment and the challenges and uncertainty that go with it.
我們仍專注於策略執行、責任承擔、敏捷性、卓越客戶服務,並持續投資以成長業務。這是一個多變數方程式,我們持續討論,且在多項因素結合下,我們仍具備獨特的提供能力。在持續推進策略性計畫的同時,我們也持續因應COVID-19環境及其伴隨的挑戰與不確定性。
Throughout the pandemic, our top priority has been consistent, the health and safety of our employees and their families, doctors and their staff and that has not changed. The situation with COVID remains very fluid. And with the rise of the Delta variant, many cities, states and countries have issued or plan to issue new guidance including mask requirements, regular testing capacity limits and vaccination mandates. Operating in this evolving environment is challenging for everyone, and we are staying as close as we can to the situation.
在整個疫情期間,我們的首要任務始終如一:員工及其家人、醫師及其員工的健康與安全,且這一點沒有改變。COVID情勢仍非常多變。隨著Delta變異株的升高,許多城市、州與國家已發布或計畫發布新的指引,包括口罩要求、定期檢測、容量限制與疫苗接種強制令。在此不斷演變的環境中營運對所有人都是挑戰,我們會盡可能密切掌握情況。
The shift from traditional analog wires and brackets to a fully end-to-end digital platform is not easy. It cannot be done without very complex and industry-leading technology and talented, passionate people. But the digital transformation in orthodontics is inevitable.
從傳統類比的鋼線與托槽轉向完整端到端的數位平台並不容易。若沒有極其複雜且業界領先的技術,以及才華洋溢、充滿熱情的人才,這是不可能做到的。但齒顎矯正的數位轉型是不可避免的。
Our technology is prevalent, touching every aspect of what we do for manufacturing excellence, where we currently produce over 750,000 unique aligners a day, to expanding our geographic footprint to over 100 markets, to building a network of over 210,000 trained Invisalign doctors and providing the technology to our doctors in a complete digital system, the Align Digital Platform.
我們的技術已廣泛普及,觸及我們所做的一切:從製造卓越(我們目前每日生產超過750,000副獨特的隱形矯正器),到將地理版圖擴展至超過100個市場,再到建立超過210,000名受訓的Invisalign醫師網絡,並透過完整的數位系統—Align數位平台(Align Digital Platform)—向醫師提供技術。
As the inventor of the leading Clear Aligner system, we've been investing in this therapy for over 24 years to get it to where it is today. And yet the majority of the market opportunity remains largely untapped, with over 500 million potential cases starts globally, align is in a rare position to address this market with the Align Digital Platform powered by 2 decades of research and development, manufacturing excellence, clinical data based on more than 11 million patients with AI machine learning and digital tools to help our doctors efficiently communicate with their patients, show and explain any issues and visualize potential treatment options. And together with doctors, we're going to unleash the power of digital for dentistry in orthodontics more than ever.
作為領先透明矯正系統的發明者,我們在過去 24 年以上持續投入這項療法,才讓它發展到今天的水準。然而,市場機會的大部分仍尚未被充分開發:全球潛在起案數超過 5 億例。Align 憑藉由 20 年研發所驅動的 Align 數位平台,結合製造卓越、基於超過 1,100 萬名患者的臨床數據、AI 機器學習與數位工具,協助醫師更有效率地與患者溝通、展示並解釋任何問題,並將潛在治療選項視覺化,因此處於能夠切入並滿足此市場的罕見有利位置。我們也將與醫師攜手,前所未有地釋放數位化在牙科正畸領域的力量。
Thank you for your time today. I look forward to speaking with you on Friday at our Investor Day. We will share more details on the Align Digital Platform and our vision and strategy to make Clear Aligner treatment available to everyone through doctors.
感謝各位今天撥冗參與。我期待在週五的投資人日與各位交流。我們將分享更多關於 Align 數位平台的細節,以及我們的願景與策略:透過醫師,讓透明矯正治療人人可及。
Now I'll turn the call over to our operator for your questions. Operator?
接下來我把電話交給接線員,進行提問環節。接線員?
Operator
Operator
(Operator Instructions) Our first question comes from Nathan Rich with Goldman Sachs.
(接線員指示)我們的第一個問題來自高盛(Goldman Sachs)的 Nathan Rich。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Joe and John, you highlighted the seasonal softness in September and that extended into October. I wonder if you could maybe just provide a little bit more detail on what you've seen in October so far and maybe how that compared to September?
Joe 和 John,你們提到 9 月出現季節性疲弱,且延續到 10 月。我想請你們再多提供一些細節,說明截至目前 10 月你們觀察到的情況,以及與 9 月相比如何?
And then as we've seen the latest COVID case spikes subside in recent weeks, have you seen the patient traffic flow that you mentioned, has that started to pick up as COVID cases have ticked down?
另外,近期最新一波 COVID 病例高峰已在近幾週回落;隨著病例數下降,你們先前提到的患者到診流量是否已開始回升?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Nate, this is John. As we said, the extended seasonality continued into September and October. And then some of the COVID uncertainty still remains, in some places, more back to normal than others. And -- but that uncertainty remains. Taking all that together, our forecast reflects that. So the total year -- the remaining for the total year reflects everything that we've seen to this date.
Nate,我是 John。如同我們所說,延長的季節性因素延續到 9 月與 10 月。此外,在某些地區,COVID 帶來的不確定性仍然存在;有些地方較接近回到常態,但——這種不確定性仍在。綜合以上因素,我們的預測已反映這些情況。因此,全年的剩餘期間(全年剩餘部分)的展望,反映了截至目前我們所看到的一切。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Okay. That's fair. I guess, Joe, maybe a follow-up. I mean you've continued to have confidence in that 20% to 30% long-term range. Maybe we'll hear more on Friday at the Analyst Day. But do you have an initial view on growth for next year? And do you feel like once this period of more pronounced seasonality is behind you, we get back to like a more normalized kind of trajectory for the business as we head into next year?
好的,合理。我想,Joe,追問一下。你們仍對長期 20% 到 30% 的區間有信心。也許週五的分析師日會談更多。但你對明年的成長有初步看法嗎?以及你是否認為,一旦這段季節性更明顯的期間過去,隨著我們進入明年,業務會回到較正常化的成長軌跡?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I mean, Nathan, just -- yes, we're growing at a pretty good pace right now, right? So it's actually above our long-term growth model, which is 20% to 30%. And as we move into 2022, we'll retain that 20% revenue growth target, and we're happy to discuss it more in detail on Friday.
Nathan,我的意思是——是的,我們目前的成長速度相當不錯,對吧?實際上高於我們的長期成長模型,也就是 20% 到 30%。隨著我們進入 2022 年,我們會維持 20% 的營收成長目標,也很樂意在週五更詳細地討論。
Operator
Operator
Our next question is from Jon Block with Stifel.
下一個問題來自 Stifel 的 Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
John, this might follow Nathan's sort of path, but let me take a different approach. The new rev range that you gave for this year, you clearly brought it up a little bit. It seems to imply a bit over $1 billion for the fourth quarter. If I assume the scanner up sequentially from the $178 million and $55 million-ish, give or take, in non-case revenue, it looks like case volume is expected to be flat to maybe even down low to mid-single digits sequentially.
John,這可能沿著 Nathan 的思路,但我換個角度問。今年你們給出的新營收區間,顯然略有上調。看起來意味著第四季會略高於 10 億美元。如果我假設掃描儀收入較前一季上升、從 1.78 億美元,以及非病例收入約 5,500 萬美元上下(大概如此),那麼看起來病例量預期將季比持平,甚至可能季比下滑低到中個位數百分比。
So a couple of things there. Is that the right way to think about things specific to case volumes? And if so -- I know you touched on this a little bit, but why sort of the different trend line versus prior to COVID, if you would, where that was more up mid-single-digit plus?
所以這裡有幾點:就病例量而言,這樣理解對嗎?如果是——我知道你稍早有提到一些——那麼相較於 COVID 之前(當時通常是季比中個位數以上成長),為什麼趨勢線會不同?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Jon, I think when you look at prior years, with COVID not in the mix, things were maybe more seasonal. And you could see some of that -- the standard patterns from like, let's say, a Q3 to Q4, given COVID and given some of the uncertainties that you have in certain economies and how they are responding and opening up, things don't always apply to mainly what's happened in the past. So that guidance that we gave is just a reflection of what we've seen.
是的,Jon。我認為當你回看過去幾年、在沒有 COVID 影響的情況下,事情可能更符合季節性,你也能看到一些——例如從第三季到第四季的標準模式。但在 COVID 以及某些經濟體所面臨的不確定性、以及它們如何應對與重啟的背景下,過去主要發生的情況不一定都適用。因此,我們給出的指引只是反映我們所觀察到的情況。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. Got it. And Joe, just a follow-up. We keep on hearing about the iOS change from Apple on privacy, and you guys have such a broad reach in terms of marketing. But I am curious if you're seeing any impact. Is it impacting leads, yes or no? And if so, could that actually continue into 2022? I would love your feedback there.
好的,了解。Joe,再追問一下。我們一直聽到蘋果在隱私方面的 iOS 變更,而你們在行銷觸及面非常廣。我很好奇你們是否看到任何影響。它是否影響到潛在客戶線索(leads),是或否?如果有,這種影響是否可能延續到 2022 年?很希望聽到你的看法。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I mean yes, Jon, it's a good question. I mean we've seen an impact on it. The thing is, there's a lot of other media you can pivot to in order to find those patients. So have we seen it and have we had to do a certain amount of pivot to do that? Yes. But as far as our marketing efforts, I wouldn't discount them in any way in the sense of that change being material in some sense in the near future.
是的,Jon,這是個好問題。我們確實看到一些影響。重點是,還有很多其他媒體管道可以轉向,以找到那些患者。所以我們有沒有看到影響、也有沒有因此做了一定程度的轉向?有。但就我們的行銷投入而言,我不會因此而以任何方式否定它們,因為就近期而言,我不認為那項變更在某種意義上會造成重大影響。
Operator
Operator
Our next question comes from John Kreger with William Blair.
下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
I'm curious, now that you've exited another kind of typical teen season, what sort of penetration do you think Invisalign has of total teen starts at this point?
我想了解,現在你們剛結束另一個典型的青少年旺季,你認為 Invisalign 目前在青少年起案總量中的滲透率大概是多少?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I mean, globally -- hey, John, it's Joe. Globally, it's less at 5%. I mean, you look at -- and we'll show you on Friday exactly what we think that is. In the United States, I think our current number is mid-teens? Yes.
嗯,我的意思是——全球來看——嗨 John,我是 Joe。全球不到 5%。我的意思是,你看——我們會在週五向你們展示我們認為的具體數字。在美國,我想我們目前的數字是十幾個百分點的中段?是的。
John, I think you know that too, we have so far to go, right? This is a superior treatment, like I said in our script. We can do 90% of the orthodontic cases are out there. It's just us continuing to work really closely with orthodontists and advertise to consumers to explain the benefits of digital orthodontics and move this forward.
John,我想你也知道,我們還有很長的路要走,對吧?這是一種更優越的治療方式,就像我在講稿裡說的。我們可以處理市面上 90% 的正畸病例。接下來就是我們持續與正畸醫師密切合作,並向消費者宣傳,解釋數位正畸的好處,推動這件事向前。
But like I said, this is inevitable. Digital is better. We know it's better. We've made it better. It's more comprehensive than it was before. It's faster, less invasive. I could go on all day. And that's what drives this company. That's our purpose. We know we'll hit it. It's just -- there's just a lot of work to get from here to there.
但就像我說的,這是不可避免的。數位化更好。我們知道它更好。我們也讓它變得更好。它比以前更全面、更快、侵入性更低。我可以講一整天。而這正是驅動這家公司的力量,這就是我們的使命。我們知道我們會達成,只是——從現在到那裡,還有很多工作要做。
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
John Charles Kreger - Partner & Co-Group Head of Healthcare Technology and Services
And that was -- Joe, that was my follow-up. As you talked to your kind of power users or maybe people that are just getting started, you've made the product better, you made the software better. What do you think is the key point of friction at this point to sort of get that adoption rate up, where I think most of us on this call sort of assume it can get to longer term?
而那——Joe,那就是我的追問。當你與你們的重度使用者,或是剛開始使用的人交流時,你們把產品做得更好、軟體也做得更好。你認為目前要提高採用率、讓它達到我們在這通電話上多數人所假設的長期水準,最大的摩擦點是什麼?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
John, I think it's the classic early adopter syndrome. The doctors who use our product almost exclusively 100% can't imagine not using our product line, right? But they're early adopters in the classical sense. There's 2 things. There's one, there's a clinical confidence people that are out there that we have to convince. And it's much easier than it is today than it was 5 years ago, given products like -- first, given products like mandibular advancement, those kind of things that extend it. And then the predictability of our products.
John,我認為這是典型的早期採用者症候群。幾乎 100% 主要使用我們產品的醫師,無法想像不使用我們的產品線,對吧?但他們在傳統意義上就是早期採用者。有兩件事:第一,是臨床信心——我們必須說服市場上那些人。而相較於 5 年前,現在要容易得多,因為有像——首先,有像下顎前移(mandibular advancement)這類產品,能把適應症延伸出去;以及我們產品的可預測性。
Secondly, it's the business equation inside the orthodontic practices that they're convinced they can actually keep up the margins and the growth capability they have for their practices. We understand that. And that's why we have programs like ADAPT that we've put together, John, that orthodontists do want to engage with us, we can show them how to really operate in a digital environment and actually exceed from a margin standpoint and a growth standpoint.
第二,是正畸診所內部的商業方程式:他們需要相信自己確實能維持利潤率,以及診所的成長能力。我們理解這點。這也是為什麼我們推出像 ADAPT 這樣的計畫,John。當正畸醫師願意與我們合作時,我們可以向他們展示如何在數位環境中真正運作,並且在利潤率與成長方面都能表現得更好。
Operator
Operator
Next question comes from Jason Bednar with Piper Sandler.
下一個問題來自 Piper Sandler 的 Jason Bednar。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Congrats on the record quarter here. A couple of questions from our side. Yes. One big picture. First for you, Joe. One of the key drivers of growth the past year has been really the adult category outpacing the teens. Really seemed like heading into this quarter could be the proof point quarter and whether that growth would flip back to teens. But adult was again stronger than teens here.
恭喜你們創下季度新高。我們這邊有幾個問題。是的,先從宏觀層面來看。第一個給你,Joe。過去一年成長的關鍵驅動因素之一,是成人類別明顯跑贏青少年。看起來進入本季前,這一季可能會成為驗證點,看看成長是否會轉回由青少年帶動。但這一季成人又再次強於青少年。
So it seems like some good staying power. So I guess, Joe, how do you think about how these 2 segments play out from here, both obviously have a ton of growth potential. But has the business for Align shifted to where we should be thinking about adult growth outpacing that of teens as we look forward to the coming quarters and years?
所以看起來確實有不錯的持續力。所以我想問一下,Joe,你怎麼看這兩個區隔接下來的發展?兩者顯然都有很大的成長潛力。但就 Align 而言,業務是否已經轉變到:在未來幾季與未來幾年,我們應該預期成人的成長會超過青少年?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, Jason, it's a good question. But I think it's -- and you'll hear a lot about this Friday, is the demand equation on this business is incredible, right? The 500 million patients we talk about could primarily be serviced through the general dentistry area and then the over 20 million that's on -- in the orthodontic side. I mean that's -- you look at that, you just -- it's a wide open marketplace. So adults have done well, teens will do well. I just think you have to have them both go up.
是的,Jason,這是個好問題。但我認為——你週五會聽到更多——這個業務的需求方程式非常驚人,對吧?我們談到的 5 億名患者,主要可以透過一般牙科領域來服務,另外在矯正端還有超過 2,000 萬名。我是說——你看這個,你就會覺得——這是一個完全開放的市場。所以成人表現會很好,青少年也會表現很好。我只是認為兩者都必須一起往上走。
And remember, they're dealing from different bases in the sense of, traditionally, 75% of our cases have been adults and 25% teens. So there is kind of a law of large number on the adult side, but the growth potential is amazing, and we're just going to go after both ends of that equation as aggressively as we can.
而且要記得,兩者的基期不同;傳統上,我們的病例有 75% 是成人、25% 是青少年。所以成人端有某種「大數法則」的影響,但成長潛力依然驚人,我們會盡可能積極地同時攻兩端。
Jason M. Bednar - VP & Senior Research Analyst
Jason M. Bednar - VP & Senior Research Analyst
Got it. Okay. That's helpful. Look forward to more on Friday then. And then maybe just more of a real-time look and also following up on Nate's question there to start out, but asking also a different way.
了解。好,這很有幫助。那就期待週五聽到更多。接著也許想更即時地看一下,同時也延續一開始 Nate 的問題,但換個方式問。
Maybe wondering if you could talk about how utilization trends have gone here month-to-month on a regional basis, September, October. And then maybe based on the treatment plans, submissions, other measures of your funnel, what does the utilization look like as we shift from October to November?
想請你談談各地區的使用率趨勢,按月來看,像是 9 月、10 月的情況。然後也許根據治療計畫、提交量以及你們漏斗的其他衡量指標,從 10 月轉到 11 月時,使用率看起來如何?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Jason, this is John. We've seen some improvements in utilization. And it's a reflection of kind of coming out of that seasonality piece of what we've talked about. And kind of navigating through COVID, but we've been happy with the utilization that we've seen as of late.
Jason,我是 John。我們看到使用率有一些改善。這反映出我們之前談到的季節性因素正在消退,也是在 COVID 的環境中逐步調整,但我們對近期看到的使用率表現感到滿意。
Operator
Operator
Our next question comes from Elizabeth Anderson with Evercore.
下一個問題來自 Evercore 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
I had a question on the gross margin line. I think you guys talked about how you're seeing maybe slightly higher manufacturing costs in Clear Aligners and then lower freight and higher freight in iTero so there's other -- higher freight cost there.
我有一個關於毛利率項目的問題。我想你們提到在透明牙套(Clear Aligners)方面可能看到製造成本略高,然後運費在透明牙套較低、但在 iTero 則較高,所以那邊還有——更高的運費成本。
So I was just wondering, as we think about some of the global supply chain issues that we've been reading about and hearing about from other companies, if you could just elaborate a little bit on what you're seeing in both of those areas.
所以我想問的是,考量我們最近讀到、也從其他公司聽到的全球供應鏈問題,你們能否多談一點你們在這兩個領域各自看到的情況?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Elizabeth, this is John. I can take that. I think when you look at our overall gross margin, broadly impacted as we talked about additional aligners as we now have ramped up, and we've seen those cases from the last several quarters as doctors make refinements and get patients in to make refinements to the care. We see an improvement there in ASP, but there's some offset in gross margin. But broadly when we look at some of the inflationary pressures and so on, we have long-term contracts.
Elizabeth,我是 John。我來回答。當你看我們整體毛利率時,正如我們提到的,主要受到額外牙套的影響,因為我們現在已經擴大產能,並且看到過去幾季的病例,醫師在做微調(refinements)時會讓患者回診以進行微調照護。我們在 ASP 上看到改善,但毛利率有一些抵銷。整體而言,談到通膨壓力等等,我們有長期合約。
We have got a supply chain where we're driving a lot of productivity and efficiencies through. So we feel we're pretty well balanced as we see some of these inflationary headwinds. Not that it's not a challenge -- it's not that it's not a challenge out there for everybody, but we feel that between the contracts we have and the efficiencies we can drive, we balance it.
我們也有一個供應鏈體系,正在推動大量的生產力提升與效率改善。因此,面對這些通膨逆風,我們覺得整體相當平衡。並不是說這不是挑戰——對每個人來說外部環境都很具挑戰——但我們認為,透過現有合約以及我們能推動的效率提升,可以把它平衡掉。
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
Elizabeth Hammell Anderson - MD & Fundamental Research Analyst
That's really helpful. And maybe I saw that in your outlook, you're obviously talking about around $100 million in share repurchases in the fourth quarter. But your cash balance is moving up nicely. And I was wondering if you could comment on what you see sort of as the -- your sort of preferred level of cash balance and if there's any potential for acceleration on the share repurchase line or things that we should consider in sort of thinking that, that should be a little bit higher than where it's been traditionally?
這很有幫助。另外我注意到你們在展望中提到第四季大約 1 億美元的庫藏股回購。但你們的現金餘額也在穩健上升。我想請你們評論一下,你們偏好的現金水位大概是什麼?以及在回購方面是否有加速的可能,或是我們在思考時是否應該把回購金額看得比過去傳統水準更高一些?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. I think when you look at on balance, Elizabeth, we're very pleased with the cash generation, almost $900 million of CFOA 3 quarters of the year. Phenomenal cash, a lot going back into the business to grow our business, make investments in some of the operating expenditures to grow our business, continue to make investments in capacity and adding capacity, getting closer to our customers.
是的。我認為整體來看,Elizabeth,我們對現金創造能力非常滿意,今年前三季 CFOA 接近 9 億美元。現金表現非常出色,其中有很多會再投入到業務中以推動成長,包含在一些營運支出上的投資來擴大業務,並持續投資產能、增加產能,讓我們更貼近客戶。
And then as we've said with our cash, we'll get back to shareholders to repurchase. So we're very happy with how things have progressed. We don't have a magical number in terms of how much cash we should have, but all things in balance, we feel like we're executing to our strategy.
然後如同我們所說,我們也會把現金回饋給股東進行回購。所以我們對進展非常滿意。我們沒有一個神奇的數字來界定應該持有多少現金,但在各項因素取得平衡的前提下,我們覺得我們正按策略執行。
Operator
Operator
Our next question comes from Jeff Johnson with Baird.
下一個問題來自 Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Joe, I wanted to start maybe on System and Services or maybe John, this for you. But where are we at as what portion of that revenue is kind of the recurring Services side as opposed to the System sales? And in 4Q, we're still hearing about a decent amount of PPP money floating around. Obviously, you've got the incremental launch coming in China and that of 5D. Should we think of 4Q being a better system quarter sequentially? Again, just with seasonality there?
Joe,我想先從系統與服務(System and Services)開始,或 John 這題給你也可以。目前那部分營收中,大概有多少比例是可重複的服務收入(Services),相對於系統銷售(System sales)?另外在第四季,我們仍聽到有不少 PPP 資金在市場上流動。再加上你們在中國的增量上市,以及 5D 的推出。就季節性而言,我們是否應該預期第四季系統端會比第三季更好?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, Jeff, this is John. I mean we've been very pleased with our sequential improvements that we've seen in the Systems and Services and Scanner and Services business. When we look at 5 quarters in a row of kind of really helping us lead the recovery out of COVID and a lot of investments that doctors are making -- our doctors are making in the digital platform, this is an excellent reflection of that. We have a lot of new doctors that started Invisalign this quarter with us, and many of them start with getting an iTero and being able to utilize that within their practice.
是的,Jeff,我是 John。我們對系統與服務、以及掃描儀與服務業務的連續改善非常滿意。當我們看到連續 5 個季度的表現,確實幫助我們帶領從 COVID 中復甦;同時醫師——我們的醫師——在數位平台上做了大量投資,這是很好的反映。本季有很多新醫師開始與我們合作使用 Invisalign,而其中許多人一開始就會先購買 iTero,並在診所內加以運用。
So we feel very good about the Scanner and Services business. About 1/3 of that business is Services. So that's recurring. And as we improve and have more of an installed base, that just grows that business. So you've got a very big and growing installed base, coupled with great products that are really driving that adoption. And especially amongst newer doctors coming in, they're coming in with that scanner to really incorporate that digital technology into their practice.
所以我們對掃描儀與服務業務感到非常有信心。這個業務大約有 1/3 來自服務,因此是經常性收入。而隨著我們改善並擴大裝機基礎(installed base),那塊業務就會持續成長。因此你有一個非常大且持續成長的裝機基礎,再加上很棒的產品,真正推動採用率。尤其是新加入的醫師,他們會搭配掃描儀進來,把數位技術真正融入他們的診所流程。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Yes. Understood. And then, Joe, maybe bigger picture question, just on kind of the return in the chair and what docs are seeing for Clear Aligners and Invisalign especially relative to braces. But we've talked to more and more docs just even over the last maybe few months who seem to be really spacing those follow-up visits in Invisalign out to 3 or even 4 months. It's cutting the chair time even in half relative to pre-COVID levels and well below braces.
是的,了解。接著,Joe,可能是更宏觀的問題,關於回到診間(return in the chair)以及醫師對透明牙套(Clear Aligners)與 Invisalign 的觀察,尤其是相對於傳統牙套(braces)。但我們跟越來越多醫師聊到,甚至就在過去幾個月,他們似乎把 Invisalign 的回診間隔拉長到 3 甚至 4 個月。相較於 COVID 之前,診間時間(chair time)甚至減半,而且也明顯低於傳統牙套。
So are you seeing the same thing? I know virtual is helping that a little bit. I think some docs even doing it without virtual just given their confidence in outcomes. But how much is that kind of driving the argument in that kind of secular push into Clear Aligners, especially with staffing issues that maybe you guys are hearing about at some of the offices, things like that?
所以你們也看到同樣的情況嗎?我知道虛擬照護(virtual)在某種程度上有幫助。我想有些醫師即使不靠 virtual,也因為對結果有信心而這麼做。但這在多大程度上推動了透明牙套的結構性滲透(secular push),尤其是你們可能也聽到一些診所有人力配置(staffing)問題之類的情況?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Jeff, that's one of the key ingredients is the productivity of a doctor's time and the productivity of the real estate within that office. In a digital kind of situation, you can remote monitor it like you do on virtual care, some other products that are out there and doctors are taking advantage of that. But also, there's a lot of confidence doctors have, too, if their patients are using the aligners and they will bring them back every so often and take a look. So that's a big part of it.
是的,Jeff,這是關鍵因素之一:醫師時間的生產力,以及診所內部空間(real estate)的生產力。在數位化的情境下,你可以像 virtual care 那樣進行遠端監測,市面上也有一些其他產品,醫師正在善用這些。但同時,醫師也有很高的信心;如果患者確實按規定配戴牙套,他們就可以隔一段時間再把患者叫回來檢查一次。所以這是很重要的一部分。
Secondly, Jeff, is it -- you can actually work with less labor content and less doctor content and people in the office and also size of the office, too. And you see a lot of orthodontists understanding that and really embracing it. There's also a referral aspect of Invisalign is once a patient has an experience with Invisalign, they're often ready to refer another patient to that doctor much more so than wires and brackets. And they benefit from that because they see an increase in their sales too.
第二點,Jeff,是你其實可以用更少的勞動投入、更少的醫師投入,以及更少的診所人員來運作,甚至診所規模也可以更精簡。你會看到很多矯正醫師理解這一點並且真正擁抱它。另外,Invisalign 還有轉介(referral)的面向:一旦患者有了 Invisalign 的體驗,他們往往更願意把其他患者轉介給同一位醫師,相較於鋼線與托槽更是如此。醫師也因此受益,因為他們也會看到銷售增加。
And we see that constantly and adapt and we focus on that and can actually predict it to a certain extent of time. So I hope I'm answering your question, Jeff, but that is the whole idea of digital and then we keep talking about our Align digital capability and being able to service a doctor through iTero, being having virtual care on both ends and having the kind of capability and horsepower that we can provide with our algorithms and the extent of our clinical capability is just -- it gives us a huge amount of breadth and capability at orthodontists.
我們一直都看到這種情況,並且會因應調整、專注於此,甚至在一定時間範圍內能夠做出某種程度的預測。所以,Jeff,我希望我有回答到你的問題;但這就是數位化的整體概念。接著我們也一直在談我們的 Align 數位能力,以及能夠透過 iTero 服務醫師、在兩端都能提供虛擬照護,並且具備我們的演算法所能提供的能力與算力,以及我們臨床能力的深度——這些都讓我們在矯正醫師端擁有非常廣的覆蓋面與能力。
Operator
Operator
Our next question comes from Brandon Couillard with Jefferies.
下一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
I actually want to switch gears. You talked quite a bit about the non-case business and the retainer business. Can you just help us understand why your share has historically lagged there? Maybe a sense of what your capture rate is today in terms of the cases that also have a follow-on retainer? And how would you sort of frame the revenue opportunity from these new initiatives?
我想換個話題。你談了不少非病例業務以及維持器(retainer)業務。你能否幫我們理解一下,為什麼你們在那一塊的市占率過去一直落後?也許可以談談你們目前的「捕捉率」大概是多少——也就是在你們的病例中,有多少後續也會搭配維持器?另外,你會如何界定這些新計畫所帶來的營收機會?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Brandon, it's a good -- it's why we highlighted it. And it's obviously why we've put money into this thing and a focus on over the last years. There are certain things in this business that we all know, but there are so many things to do and focus on that sometimes something that's so obvious like that lacks the attention that you want to give to it. And we've been talking about this over time. So beginning of this year, put a team together to really go after those things.
Brandon,這是個好問題——也正是我們為什麼特別把它拿出來強調。這也顯然是我們為什麼在過去幾年投入資金並聚焦在這件事上。這個業務裡有些事情大家都知道,但要做、要聚焦的事情太多了,有時候像這樣很明顯的事反而沒有得到你希望給它的關注。我們也談了一段時間了。所以今年年初,我們組建了一個團隊,專門去推進這些事情。
It's hard to say the reason why. It's just we haven't been as focused on retention as we need to be. And many orthodontists like they make their own retainers. They do it because we just haven't been competitive in the sense of how we can deliver, how fast we can deliver, how easy we make it for them. But I guarantee you, if you go out, Brandon, and you query even orthodontists that seldom use our retainers, they'll tell you we make the best retainers in the world.
很難說原因是什麼。就是我們在維持(retention)這件事上,沒有像應該的那樣聚焦。而且很多矯正醫師會自己做維持器。他們這麼做,是因為我們在交付方式、交付速度、以及讓他們使用起來有多容易等方面,競爭力不夠。但我可以向你保證,Brandon,如果你去問那些很少使用我們維持器的矯正醫師,他們也會告訴你:我們做的是全世界最好的維持器。
And we should, when you make 750,000 unique parts a day, right? We know what we're doing, the fits are exquisite when you have an iTero scanner to be able to do that. And we set this thing up as a play for doctors that they can feel confident that we'll get these retainers to them in a quick amount of time. They're going to be terrific retainers, something they're proud to really get to their patients. And we've had great feedback on this so far.
而且我們本來就應該做到——畢竟我們每天生產 75 萬個獨一無二的零件,對吧?我們知道自己在做什麼;當你有 iTero 掃描器能做到這件事時,貼合度非常精準。我們把這件事定位成一個給醫師的方案,讓他們有信心:我們能在很短時間內把維持器交到他們手上;維持器品質會非常好,是他們願意自豪地交付給病患的產品。到目前為止,我們收到的回饋非常好。
So I can't apologize for the past or give you the whole history why we haven't done it, but I feel really good about the progress we've made so far.
所以我沒辦法為過去道歉,或把我們為什麼沒做好的完整歷史都講一遍,但我對目前為止我們取得的進展感到非常有信心。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
That's great. And then just a question on the scanner business. I mean pretty remarkable strength for a while now. Can you just help us understand like where kind of the sources of this momentum? And is the NIRI study the type of data set that can move the needle with GPs?
很好。接著想問掃描器業務。我是說,這段時間以來的強勁表現相當驚人。你能否幫我們理解一下,這股動能的來源大概是哪些?另外,NIRI 研究是否屬於那種能夠推動一般牙醫(GPs)採用的資料集?
You all often talk about clinical studies, especially with intraoral scanners, but just trying to get a sense of how significant being able to go and have this data that might be for a GP that doesn't use digital impressioning today or might be on the fence.
你們常常談到臨床研究,尤其是在口內掃描器方面;我只是想了解,能夠拿著這些資料去溝通,對於目前還沒有使用數位取模的一般牙醫,或是仍在觀望的一般牙醫而言,影響力到底有多大。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I think NIRI really helps. I really do. It's one of those -- in electronics, we all know there's killer apps, right, killer applications? When you can see caries, cavities, right, we use the clinical term. But when you can see cavities without ionizing radiation, and Brandon, what's amazing when you see this, too, what happens is the enamel almost becomes invisible. It's almost translucent. You can see through the enamel right to where the caries is. And there's a certain amount of training that has to be done in order to do it.
是的。我認為 NIRI 真的很有幫助,我確實這麼認為。這有點像——在電子產業我們都知道有所謂的 killer app(殺手級應用),對吧?當你能看到齲齒、蛀牙(我們用臨床術語),而且是不需要電離輻射就能看到蛀牙時,Brandon,更令人驚訝的是,當你看到這個影像時,琺瑯質幾乎變得看不見,幾乎是半透明的。你可以透過琺瑯質直接看到齲齒所在的位置。當然,為了能做到這點,需要一定程度的訓練。
And look, I grew up in an ionizing radiation business. I know what it is in CT and X-ray and it's -- that radiation component is better today than it used to be, but it still exists and patients are still concerned with it over time. And to be able to do this in a sense in a safe way and in a quick way like we do it. You know what it is to put bitewings in a chair, and it's terrible in a test chair, right? Bite down, turn your head sideways, I could go through it all day.
而且你看,我是在電離輻射的產業長大的。我知道 CT 和 X 光是怎麼回事——輻射這個部分現在比以前好很多,但它仍然存在,而病患長期以來仍然會對此感到擔憂。能夠以我們這種方式,在安全且快速的情境下做到這件事。你也知道把咬翼片(bitewings)放到椅旁是什麼感覺,那在檢查椅上很糟糕,對吧?咬住、把頭轉向一邊——我可以講一整天。
And this is a quick scan, 1 minute scan, 1.5 minute scan. It pops up on the screen. You can have a conversation with the patient and say, "There it is and what it deals with." So yes, I think it's a killer application. Will it convince all GPs to buy iTero? No. But then you have to look at exocad, that critical workflow between labs and GPs really sets us up nicely for restorative pieces.
而這只是一次快速掃描,1 分鐘掃描、1.5 分鐘掃描。影像就會出現在螢幕上。你可以和病患對話,說:「就在這裡,以及這代表什麼。」所以是的,我認為這是殺手級應用。它會說服所有一般牙醫去買 iTero 嗎?不會。但接著你還要看 exocad——實驗室與一般牙醫之間那個關鍵工作流程,確實讓我們在修復(restorative)相關的項目上具備很好的布局。
Soon to announce Smile Architect, which really allows doctors to use restorative orthodontics as a standard of care. We'll talk about that more Friday. So -- and look, I'm biased. I've been in the -- I'd say, the medical imaging equipment business for 15 years of my life, counting iTero, this is the best scanner in the marketplace. And then we're just out to show it and to prove it.
我們很快會宣布 Smile Architect,它真正讓醫師能把修復性矯正(restorative orthodontics)作為標準照護(standard of care)。我們週五會再多談一些。所以——而且你看,我有偏見。我在醫療影像設備產業待了 15 年的人生(把 iTero 也算進去),這是市場上最好的掃描器。接下來我們就是要把它展示出來、證明出來。
Operator
Operator
Our next question is from Chris Cooley with Stephens.
下一個問題來自 Stephens 的 Chris Cooley。
Christopher Cook Cooley - MD
Christopher Cook Cooley - MD
Congratulations on the record quarter. Just for me, as we all start looking forward to the upcoming event here this Friday and Saturday, maybe a bigger picture question. As we think about the business, you've made significant investments in technology not only in pioneering the category, but expanding its indications for use. You subsequently invested in chairside, really facilitating the diagnostic aspect.
恭喜創下紀錄的一季。對我來說,當我們都開始展望本週五、週六即將到來的活動時,想問一個更宏觀的問題。從業務角度來看,你們在技術上做了大量投資,不僅是開創這個品類,也擴大了適應症(indications for use)。之後你們又投資了椅旁(chairside),真正促進了診斷面向。
And as the business is now kind of inflecting here 2 straight quarters of $1 billion plus, do we think about the next stage of investment really kind of going back to a prior question being tools that enable or enhance the productivity of the clinician or patient flow?
而當業務現在似乎正在轉折——連續兩季都超過 10 億美元——我們是否應該把下一階段的投資,理解為回到先前某個問題:也就是那些能夠讓臨床醫師生產力提升、或改善病患流程(patient flow)的工具?
Is it more to marketing at the consumer and clinical level? I'm just kind of thinking about how the business now pivots for that next stage of continued growth at this greater scale. And I have just one quick follow-up after that, if I may.
還是會更多投入在面向消費者與臨床端的行銷?我只是想理解,當業務在更大的規模下進入下一階段持續成長時,接下來會如何調整方向。另外,如果可以的話,我後面還有一個很快的追問。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Chris, it's a really good question because obviously, as we're going through our AOP for next year and putting those things together. But when you say pivot, I wouldn't use the word pivot, I'd say that we extend what we're doing. And then we place bets accordingly and where we think we'll get the best return. We -- I've got to continue advertising. We have [a peer] system. We have a wonderful brand. We have to leverage that piece.
Chris,這是個非常好的問題,因為很顯然我們正在為明年的 AOP(年度營運計畫)做規劃並把這些事情整合起來。但你說「pivot(轉向)」的話,我不會用 pivot 這個字;我會說我們是在延伸我們正在做的事。然後我們會依據我們認為能取得最佳回報的地方來下賭注。我們——我必須持續投放廣告。我們有 [a peer] 系統。我們有很棒的品牌。我們必須把這一塊槓桿化。
But specifically, and this goes to the last questions we had, too, doctor productivity is a big deal. And when you look at our Align Digital Platform, inherently, that's what it's about. It's how do you make doctors more productive to make sure that we don't go back and forth with a ClinChecks? Or how do we make sure that from our standpoint that we can respond quickly to customer issues. And we're investing heavily in all those things and making good progress.
但更具體地說,這也呼應剛才的問題:醫師生產力非常重要。當你看我們的 Align 數位平台,本質上它就是在做這件事。也就是:如何讓醫師更有效率,確保我們不需要在 ClinCheck 上來回反覆?或者從我們的角度,如何確保我們能快速回應客戶問題。我們在這些方面投入很大,也取得了不錯的進展。
It's expensive. A lot of things that you have to do when you're really grounded in software and making those changes. We have really great talent here that knows how to do that. We've been actually working the productivity of ClinCheck and those things for 3 to 4 years and it's just starting to bring technology to the marketplace. So you're right. We're not pivoting toward that. We've been investing in it. But you'll see the combination of that more and more as we enter next year in the second half of next year too. John, anything to add?
這很昂貴。當你真正以軟體為核心並進行那些變更時,有很多事情必須做。我們這裡有非常優秀的人才,知道該怎麼做。我們其實已經在 ClinCheck 的生產力以及相關事項上投入了 3 到 4 年,現在才剛開始把技術帶到市場上。所以你說得對。我們不是轉向那裡;我們一直在投資。但你會看到這些的組合在明年、尤其是明年下半年會越來越明顯。John,有什麼要補充的嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
No. I think that's the investments that we continue to make. It's about productivity. It's about growing in this digital orthodontics and our doctors expect it. And our tools will provide that.
沒有。我認為這就是我們持續投入的方向。重點在生產力。重點在數位矯正的成長,而我們的醫師也期待如此。我們的工具會提供這些。
Christopher Cook Cooley - MD
Christopher Cook Cooley - MD
That's great. And if I could just squeeze in a quick follow-on. I just want to make sure it doesn't look out of proportion, but I just want to make sure we didn't miss something there on the deferred piece in the quarter, I think it was approximately $84 million. Anything just COVID-related that we should be mindful of there? Or is that just normal course of business when we look at the deferred revenue component for the 3Q?
很好。如果我可以再擠一個很快的追問。我只是想確認一下,避免看起來比例失衡,但我想確保我們沒有漏掉本季遞延(deferred)那一塊的某些因素,我記得大約是 8,400 萬美元。有沒有任何與 COVID 相關、我們需要特別留意的事情?還是說,當我們看第三季遞延收入(deferred revenue)這個項目時,這只是正常的業務進程?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Chris. It's completely normal course of business, nothing COVID-related within there. Just deferred revenue that we'll recognize in future periods.
謝謝你,Chris。這完全是正常的業務流程,裡面沒有任何與 COVID 相關的因素。只是遞延收入,我們會在未來期間予以認列。
Operator
Operator
Our next question comes from Mike Ryskin with Bank of America.
我們的下一個問題來自美國銀行(Bank of America)的 Mike Ryskin。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
A couple of quick ones for me, but I'll try to tie them together into one, on the Scanners and Service revenue. I noted that your digitally submitted cases continues to grind higher pretty close to hitting 90% maybe in a year or 2. I'm just wondering, as you continue to place iTeros into the field, how often are you sort of placing a second or third unit versus getting a new one out there versus a competitor placement where you're displacing someone else potentially?
我這邊有幾個很快的問題,但我會試著把它們串在一起,關於掃描器與服務收入。我注意到你們數位提交的案例比例持續緩步上升,可能在一到兩年內就接近 90%。我想請教的是,隨著你們持續在市場上部署 iTero,你們有多常是在同一家診所放置第二台或第三台設備,相較於把新設備放到新的客戶那裡,或是透過競品替換、把別人的設備取代掉?
And then as a follow-on to that, sort of building off of, I think Elizabeth's question earlier on the supply chain. Anything specific to semis that we should be thinking about? It's just a question that's come up a lot, some of our other names, I want to make sure we tie that off as far as it relates to Scanners.
接著延伸一下,呼應我想 Elizabeth 先前關於供應鏈的問題。就半導體方面,有沒有任何我們需要特別留意的事項?這個問題在我們其他一些公司名稱上被問到很多,我想確認就掃描器相關而言,我們是否可以把這點釐清。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Mike, from a Scanner standpoint is obviously, we have a great scanner. And I think your question asked more about saturation more than anything. Our feeling is you got 2 million dentists out there or orthodontists, right. And each of them actually, if you're going to run a digital practice, you need more than one scanner. You need a scanner per chair. So you think, let's just say, the average doc has 3 chairs and there's 2 million doctors out there. We're just touching this thing.
Mike,就掃描器而言,很明顯我們有一款很棒的掃描器。我想你的問題更多是在問市場飽和度。我們的看法是,外面大約有 200 萬名牙醫或齒顎矯正醫師,對吧。而且如果你要經營數位化診所,其實需要不只一台掃描器;你需要每張診療椅配一台掃描器。所以你想想,假設平均每位醫師有 3 張診療椅,外面有 200 萬位醫師,我們才剛開始觸及這個市場。
We've got a 50,000 unit installed base. And obviously, this is a growth equation. It's not one where we're looking to plan out in some time. And obviously, it's a portfolio of churns over time because the technology moves fast too. So it creates some of its own demand through obsolescence, too. John, on the supply?
我們目前的裝機基數是 50,000 台。很明顯,這是一個成長方程式;我們不是在看某個時間點就把它規劃完。而且隨著時間推移,產品組合也會有汰換,因為技術進步很快。它也會因為設備過時而創造出一部分自身的需求。John,供應方面呢?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And from a supply standpoint, obviously, we're mindful of concerns and things that go on from a global supply chain, but we feel comfortable that between the inventory we have and some of the things that we've been able to do that we can manage through any supply chain concerns that are out there.
就供應面而言,當然我們會留意全球供應鏈的疑慮與各種狀況,但我們有信心,憑藉我們現有的庫存以及我們已經能做到的一些措施,我們可以管理並度過任何可能出現的供應鏈疑慮。
Operator
Operator
Our next question is from [Devin Misra] with Berenberg.
我們的下一個問題來自 Berenberg 的 [Devin Misra]。
Unidentified Analyst
Unidentified Analyst
[Dev] here for Ravi from Berenberg. I want to kind of revisit the marketing side. I think you guys have been ramping up marketing spend and the long list of things with very large percentage increases noted earlier. Where are you seeing higher ROI in regards to marketing? Are there any specific regions?
[Dev] 代 Ravi 提問,來自 Berenberg。我想回到行銷面。你們似乎一直在提高行銷支出,先前也提到一長串項目都有非常高的百分比增幅。你們在哪些行銷面向看到更高的投資報酬率(ROI)?是否有任何特定地區?
And then also just going back to a question on growth of teens versus adults. If we kind of look at the marketing spend on things that you've noted, it seems like a focus is on the teen side, which is kind of indicative that, that's where you'll see more growth and stronger returns. So any color around that? And then I have a quick follow-up.
另外再回到青少年與成人成長的問題。如果我們看你們提到的行銷支出項目,似乎重點放在青少年端,這也暗示你們認為那裡會有更高的成長與更強的回報。能否補充一些說明?然後我還有一個簡短的追問。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. First of all, from a marketing spend standpoint, I mean, we really do understand, by region, our kind of return on investment and what we get. I'm not going to share that over the phone, but we're very aware of that and what it is. We also -- when you asked about the teen advertisements, there's a seasonality for teens around the world, too. So you'll see like in the quarter we just came out of in the second quarter, we were going into the teen season. It's big in China, big in the States.
好的。首先,就行銷支出而言,我們確實能按地區掌握我們的投資報酬率以及能獲得什麼回報。我不會在電話上分享細節,但我們非常清楚這些數據與其意涵。另外,當你問到青少年廣告時,青少年在全球也有季節性。因此你會看到像我們剛結束的這一季、第二季,我們正進入青少年旺季;在中國很大,在美國也很大。
And so you'll see a larger part of our advertising budget go toward that in order to capture that demand. But yes, this is part of how we go to market. We have a great brand. That brand needs to be enhanced with patients, and we want those patients going to doctors asking for Invisalign. And we have some very good capability here from a marketing standpoint to exercise that. John, anything?
因此你會看到我們較大一部分的廣告預算會投向那裡,以便捕捉需求。但沒錯,這就是我們的市場進入方式之一。我們有很強的品牌,而這個品牌需要在患者端被強化;我們希望患者去找醫師並主動要求 Invisalign。從行銷角度來看,我們在這方面有很好的能力可以發揮。John,有要補充的嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
And what we've learned over time is we're -- it's not one size fits all across all the markets. You're trying to maximize return on investment. And in certain markets, you're doing things that are different than others, maybe more established markets, you try something different. Maybe other markets that we have, where we can advertise, we try different things.
我們長期學到的是——各個市場並不是一套做法通用所有地方。你要做的是把投資報酬率最大化。在某些市場,你做的事情會和其他市場不同;也許在較成熟的市場,你會嘗試不同的方法。也許在我們能投放廣告的其他市場,我們也會嘗試不同的做法。
But I think the key is we understand what levers to pull. We've learned a lot over the last several years. We're very excited about these opportunities. And as Joe said, we have the best brand, the best global brand out there, and we want to be able to reach those potential patients in the way that they are living their lives. And that's the philosophy that we have. And we talk a lot about that front end, the top of the funnel metrics, and we're very excited about what we're seeing as we've gone through the last several quarters.
但我認為關鍵在於,我們知道該拉哪些槓桿。過去幾年我們學到很多。我們對這些機會感到非常興奮。正如 Joe 所說,我們擁有最好的品牌、全球最好的品牌,我們希望能以符合潛在患者生活方式的方式觸及他們。這就是我們的理念。我們也常談到前端、漏斗頂端的指標;而且在過去幾個季度的推進中,我們對所看到的成果感到非常振奮。
Unidentified Analyst
Unidentified Analyst
Okay. Great. And then kind of following up on that direct-to-consumer focus question earlier on. There was a launch of that teeth whitening solution. And a couple of years ago, there was a Align shops that, via litigation with SEC, was kind of a focus point there.
好的,很好。接著追問先前關於直接面向消費者(direct-to-consumer)聚焦的問題。你們推出了那個牙齒美白解決方案。幾年前也有 Align shops,並且透過與 SEC 的訴訟,當時那件事成為一個焦點。
So as we envision kind of where the direct-to-consumer side of Align business goes, how does that teeth whitening solution and how does that fit in? I'm trying to see it seems like there's a big push toward direct consumer with the -- with that side coming up. So any color on that would be helpful.
所以當我們想像 Align 業務的直接面向消費者這一端未來會走向哪裡時,那個牙齒美白解決方案要如何納入?它在其中扮演什麼角色?我試著理解,看起來你們在那一端有很大的推進力。所以如果能提供一些說明會很有幫助。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I mean if your question implies a direct-to-consumer kind of a moat, that's not us. It's not what we do. It's about what -- but we always have an e-commerce site. We have a great brand called Invisalign. Patients ask us all the time for whitening cleansers, chewies, things associated with it. And we're just exercising that capability.
我的意思是,如果你的問題是在暗示我們要建立某種直接面向消費者的護城河,那不是我們;那不是我們在做的事。不過我們一直都有電商網站。我們有一個很棒的品牌叫 Invisalign。患者常常問我們美白清潔產品、咬膠(chewies)以及相關用品。我們只是把這項能力運用起來。
It's one with the whitening standpoint, we probably should have been more aggressive on before. But again, it's one of those things that we decided to focus on recently. And we're getting great feedback from the doctors in doing that. And so it only makes sense. It's classic brand extension, and we're going to leverage that Invisalign brand as well as we can.
就美白而言,我們可能早就應該更積極一些。但同樣地,這是我們最近才決定要聚焦的事情之一。而且我們在這方面也收到醫師非常好的回饋。所以這樣做很合理。這是典型的品牌延伸,我們會盡可能善用 Invisalign 這個品牌。
Operator
Operator
We have reached the end of the question-and-answer session. At this time, I'd like to turn the call over to Shirley Stacy for closing comments.
我們已到達問答環節的結束。此時,我想把電話交給 Shirley Stacy 作結語。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you, operator. Thank you, everyone, for joining us today. This concludes our conference call. We look forward to speaking to you again on Friday at the Align 2021 Investor Day in conjunction with our GP Growth Summit here in Las Vegas. If you have any future questions, please contact Investor Relations. And thank you for your time, and have a great day.
謝謝你,接線員。也謝謝各位今天加入我們。本次電話會議到此結束。我們期待在週五於拉斯維加斯、配合我們的 GP Growth Summit 舉行的 Align 2021 投資人日(Investor Day)再次與各位交流。如有任何後續問題,請聯絡投資人關係部門。也謝謝各位撥冗,祝各位有美好的一天。
Operator
Operator
This concludes today's conference. You may disconnect your lines at this time, and we thank you for your participation.
今天的會議到此結束。您現在可以掛斷電話線,感謝您的參與。